Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and ...
Pulse Biosciences recently reported first patient treatments in a multi-center, first-in-human feasibility study of its FDA-cleared nPulse Vybrance Percutaneous Electrode System using nanosecond ...
Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.
12d
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to ...
Nanosecond PFA Cardiac Surgical System for ablation of cardiac tissue to be highlighted in presentation and poster sessions. “We believe the Nanosecond PFA Cardiac Surgical System has the potential to ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Pulse Biosciences (NASDAQ:PLSE) will release its quarterly earnings report on Thursday, 2026-02-19. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Pulse ...
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s ...
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...
Clinical Data on Benign Thyroid Nodule Ablation to be highlighted in presentation “We believe the differentiated nPulse Vybrance Percutaneous Electrode system is setting a new standard for safety, ...
Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results